Forte Biosciences (FBRX) Research & Development (2016 - 2026)
Forte Biosciences (FBRX) posted quarterly Research & Development of $20.3 million for Q1 2026, up 62.02% year-over-year from $12.5 million in Q1 2025, and down 5.86% quarter-over-quarter from $21.6 million in Q4 2025.
Forte Biosciences (FBRX) Research & Development (2016 - 2026) Analysis & Trends
Forte Biosciences (FBRX) has reported Research & Development for 11 consecutive years, with $20.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Research & Development rose 62.02% year-over-year to $20.3 million; the TTM figure through Mar 2026 stood at $65.4 million (up 126.13% YoY), while the FY2025 annual figure was $57.6 million, up 178.3% from the prior year.
- Research & Development eased to $20.3 million in Q1 2026 per FBRX's latest filing, from $21.6 million in the prior quarter.
- Across five years, Research & Development topped out at $21.6 million in Q4 2025 and bottomed at $693000.0 in Q1 2022.
- Historically, Research & Development has averaged $7.4 million across 5 years, with a median of $5.6 million in 2024.
- Annual changes were most pronounced in 2022 — Research & Development slumped 79.14% — and 2023, when it soared 590.76%.
- Forte Biosciences' Research & Development stood at $2.5 million in 2022, then soared by 43.37% to $3.6 million in 2023, then soared by 42.42% to $5.1 million in 2024, then surged by 324.92% to $21.6 million in 2025, then slipped by 5.86% to $20.3 million in 2026.
- Business Quant data shows FBRX's Research & Development at $20.3 million in Q1 2026, $21.6 million in Q4 2025, and $15.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Forte Biosciences | 1.63 Bn | 1.28 Bn | - | 22.19 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 22.19 Mn |
| Mar 31, 2026 | 20.32 Mn |
| Dec 31, 2025 | 21.59 Mn |
| Sep 30, 2025 | 15.05 Mn |
| Jun 30, 2025 | 8.47 Mn |
| Mar 31, 2025 | 12.54 Mn |
| Dec 31, 2024 | 5.08 Mn |
| Sep 30, 2024 | 5.72 Mn |
| Jun 30, 2024 | 5.59 Mn |
| Mar 31, 2024 | 4.32 Mn |
| Dec 31, 2023 | 3.57 Mn |
| Sep 30, 2023 | 6.37 Mn |
| Jun 30, 2023 | 7.14 Mn |
| Mar 31, 2023 | 4.79 Mn |
| Dec 31, 2022 | 2.49 Mn |
| Sep 30, 2022 | 1.38 Mn |
| Jun 30, 2022 | 1.03 Mn |
| Mar 31, 2022 | 693,000.00 |
| Dec 31, 2021 | 1.35 Mn |
| Sep 30, 2021 | 5.66 Mn |